Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
Aged
Aged, 80 and over
Alzheimer Disease
/ diagnosis
Anxiety
/ diagnosis
Biomarkers
Cognitive Dysfunction
/ diagnosis
Cross-Sectional Studies
Depression
/ diagnosis
Diagnostic Self Evaluation
Disease Progression
Female
Follow-Up Studies
Gray Matter
/ diagnostic imaging
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Memory Disorders
/ diagnosis
Mental Status and Dementia Tests
Middle Aged
Neocortex
/ diagnostic imaging
Positron-Emission Tomography
Prodromal Symptoms
Biomarkers
Neuroimaging
Pathological ageing
Preclinical Alzheimer’s disease
Psychoaffective factors
Subjective cognitive decline
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
08 07 2019
08 07 2019
Historique:
received:
20
12
2018
accepted:
13
06
2019
entrez:
10
7
2019
pubmed:
10
7
2019
medline:
17
7
2020
Statut:
epublish
Résumé
Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer's disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk. Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures. Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups. Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic.
Sections du résumé
BACKGROUND
Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer's disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk.
METHODS
Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures.
RESULTS
Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups.
CONCLUSIONS
Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic.
Identifiants
pubmed: 31286994
doi: 10.1186/s13195-019-0514-z
pii: 10.1186/s13195-019-0514-z
pmc: PMC6615169
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT01638949']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : Fondation Plan Alzheimer
ID : Alzheimer Plan 2008-2012
Pays : International
Organisme : Programme Hospitalier de Recherche Clinique (FR)
ID : PHRCN 2011-A01493-38 and PHRCN 2012 12-006-0347
Pays : International
Organisme : Agence Nationale de la Recherche
ID : LONGVIE 2007
Pays : International
Organisme : Association France Alzheimer et maladies apparentées (FR)
ID : AAP 2013
Pays : International
Références
Cereb Cortex. 2019 May 1;29(5):1889-1899
pubmed: 29668866
Alzheimers Dement. 2019 Mar;15(3):465-476
pubmed: 30555032
Arch Neurol. 2012 Feb;69(2):223-9
pubmed: 22332189
Biol Psychiatry. 2008 Mar 15;63(6):609-18
pubmed: 17720148
J Neurosci. 2008 Jun 11;28(24):6174-81
pubmed: 18550759
Neurobiol Aging. 2006 Dec;27(12):1751-6
pubmed: 16309795
Neurology. 2008 Oct 7;71(15):1152-9
pubmed: 18838662
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S99-S107
pubmed: 26402087
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S109-14
pubmed: 26402081
Am J Geriatr Psychiatry. 2015 Sep;23(9):985-93
pubmed: 25746485
Sci Rep. 2017 Aug 31;7(1):10160
pubmed: 28860449
Int J Geriatr Psychiatry. 2012 Apr;27(4):394-400
pubmed: 21560161
Neurology. 2012 Sep 25;79(13):1332-9
pubmed: 22914828
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Psychol Med. 2004 Nov;34(8):1495-506
pubmed: 15724880
Brain. 2010 Apr;133(Pt 4):1163-72
pubmed: 20375138
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neurol. 2004 Jun;251(6):671-5
pubmed: 15311341
Neuropsychologia. 2012 Oct;50(12):2880-6
pubmed: 22940426
Dement Geriatr Cogn Disord. 2010;29(1):75-81
pubmed: 20110703
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S141-50
pubmed: 26402076
Neurobiol Aging. 2003 Jan-Feb;24(1):95-103
pubmed: 12493555
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
BMC Psychiatry. 2011 Jul 01;11:108
pubmed: 21722382
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
J Neuropsychiatry Clin Neurosci. 2009 Spring;21(2):199-205
pubmed: 19622691
Brain. 2008 Jan;131(Pt 1):60-71
pubmed: 18063588
Alzheimers Dement. 2017 Jul;13(7):783-791
pubmed: 28034600
Am J Geriatr Psychiatry. 2011 Apr;19(4):327-34
pubmed: 21427641
Int J Geriatr Psychiatry. 2001 Feb;16(2):168-74
pubmed: 11241722
Brain Connect. 2013;3(4):353-62
pubmed: 23627661
Alzheimers Dement. 2014 May;10(3):319-27
pubmed: 23871264
Neurology. 2015 Jul 7;85(1):56-62
pubmed: 26048028
J Anxiety Disord. 2013 Aug;27(6):567-75
pubmed: 23298889
Alzheimers Dement (Amst). 2016 Dec 18;5:23-34
pubmed: 28054025
Neurocase. 2005 Feb;11(1):14-25
pubmed: 15804920
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
Alzheimers Dement (Amst). 2015 May 02;1(2):194-205
pubmed: 27239504
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
J Alzheimers Dis. 2015;49(4):1115-22
pubmed: 26639956
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):11-6
pubmed: 22001316
Ageing Res Rev. 2016 Sep;30:25-48
pubmed: 26827786
Neurology. 2006 Sep 12;67(5):834-42
pubmed: 16966547
Alzheimers Dement. 2010 Jan;6(1):11-24
pubmed: 20129317
Int J Aging Hum Dev. 1997;45(3):207-21
pubmed: 9438876
Dement Geriatr Cogn Disord. 2007;24(3):213-9
pubmed: 17690554
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Alzheimers Dement. 2015 Jun;11(6):e1-120
pubmed: 26073027
Rev Neurosci. 2010;21(3):187-221
pubmed: 20879692
Alzheimers Dement. 2014 Jan;10(1):99-108
pubmed: 23867795
Arch Gerontol Geriatr. 2013 Jul-Aug;57(1):110-5
pubmed: 23462582
J Am Geriatr Soc. 2004 Dec;52(12):2045-51
pubmed: 15571540
Brain Imaging Behav. 2019 Apr;13(2):554-563
pubmed: 29744801
Neurology. 2012 Oct 9;79(15):1570-7
pubmed: 22972644
JAMA Psychiatry. 2016 May 1;73(5):525-31
pubmed: 26982217
Sleep Sci. 2015 Jan-Mar;8(1):36-41
pubmed: 26483941
J Affect Disord. 2002 Nov;72(2):157-65
pubmed: 12200206
Neurology. 2008 Apr 29;70(18):1601-7
pubmed: 18443310
J Neurosci. 2012 Nov 14;32(46):16265-73
pubmed: 23152610
Neurology. 2015 Nov 24;85(21):1852-8
pubmed: 26511452
Front Psychiatry. 2014 Apr 23;5:40
pubmed: 24795656
Alzheimers Dement. 2015 Nov;11(11):1385-92
pubmed: 25667997
Acta Neurol Scand. 2013 May;127(5):344-50
pubmed: 23215819
Neurobiol Aging. 2009 Jan;30(1):112-24
pubmed: 17630048
Alzheimers Dement. 2014 Jan;10(1):93-8
pubmed: 23562429
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9
pubmed: 26402082
Am J Psychiatry. 1982 Sep;139(9):1136-9
pubmed: 7114305
J Gerontol A Biol Sci Med Sci. 2016 Sep;71(9):1210-5
pubmed: 26946100
Int J Geriatr Psychiatry. 2009 Feb;24(2):190-6
pubmed: 18642390
Gerontologist. 2013 Jun;53(3):462-73
pubmed: 22961464
Alzheimers Dement (Amst). 2015 Mar 1;1(1):33-40
pubmed: 25938132
Annu Rev Clin Psychol. 2017 May 8;13:369-396
pubmed: 28482688
J Alzheimers Dis. 2015;43(2):677-86
pubmed: 25114076
Int Psychogeriatr. 2013 Aug;25(8):1307-15
pubmed: 23693133
Alzheimers Dement. 2014 Jan;10(1):76-83
pubmed: 23375567
JAMA Psychiatry. 2015 Mar;72(3):284-91
pubmed: 25629787
J Gerontol B Psychol Sci Soc Sci. 2019 Jan 10;74(2):202-211
pubmed: 28633326
JAMA Neurol. 2015 Apr;72(4):446-54
pubmed: 25706191
Aging Ment Health. 2017 May;21(5):532-536
pubmed: 26689628
J Neurosci. 2015 Jul 22;35(29):10402-11
pubmed: 26203136
Br Med Bull. 2014 Dec;112(1):71-81
pubmed: 25274571
Alzheimers Dement. 2010 May;6(3):239-46
pubmed: 20451872
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
J Alzheimers Dis. 2010;19(1):137-45
pubmed: 20061633
J Alzheimers Dis. 2015;46(1):63-73
pubmed: 25697700
Sleep. 2013 Sep 01;36(9):1327-34
pubmed: 23997365
Brain. 2017 Dec 1;140(12):3317-3328
pubmed: 29194503
Arch Gen Psychiatry. 2010 Apr;67(4):414-22
pubmed: 20368517